AbCellera reports positive Phase 2 results for menopause drug ABCL635

AbCellera announced on August 10, 2026 that the Phase 2 portion of its Phase 1/2 trial of ABCL635, an investigational NK3R antagonist antibody, met its primary efficacy endpoints, achieving statistically significant reductions in both frequency and severity of moderate-to-severe vasomotor symptoms at week 4 compared to placebo after a single dose.¹ The drug is being developed as a non-hormonal, long-acting, subcutaneous treatment for moderate-to-severe vasomotor symptoms due to menopause.¹

The trial was a randomized, double-blind, placebo-controlled, multicenter study that enrolled 92 postmenopausal women who were having roughly 10 moderate or severe hot flashes a day on average.¹ Patients received a single subcutaneous 600 mg dose of ABCL635 or placebo, in a 1:1 ratio.¹

On frequency, the ABCL635 group saw an 8.8 mean reduction in daily moderate and severe events by week 4, versus 3.5 for placebo, for a placebo-adjusted difference of 5.3 events, with a p-value below 0.001.¹ In percentage terms, the treatment group's frequency fell 83% versus 33% for placebo, a 50-point placebo-adjusted gap.¹ On severity, ABCL635 patients improved by 1.4 points on average compared with 0.3 for placebo, a placebo-adjusted difference of 1.1 points, again with p<0.001.¹

The drug also produced meaningful improvements in sleep scores and patient global impression of change.¹ On safety, the company said no patients on ABCL635 had serious or severe adverse events, and none discontinued the study due to side effects over the four-week period. The most frequently reported adverse events exceeding placebo rates were headache, fatigue, and injection site reaction, according to the release.

AbCellera plans to discuss the data further on an investor call held the same day. The trial is registered as NCT07118891.¹